Search for a trial

T cell homeostasis after ATG induced lymphocytopenia in renal transplant patients; studied through in vivo 2H2O labeling

To get more insight into the T cell homeostasis in lymfocytopenic, ATG treated patients and normocytopenic patients treated with standard maintenance immunosuppressive drug therapy.

Prognosis of Idiopathic CD4 Lymphocytopenia in children

- The primary research objective is to estimate the prognosis of children affected by ICL. - A secondary research objective is to explore the heredity of ICL between first degree family members.

Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

This study has been transitioned to CTIS with ID 2024-510800-35-00 check the CTIS register for the current data. Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and…

Convalescent Antibody-Mediated Treatment of COVID-19 Infections in Patients with B-cell dysfunction, a Randomized Trial (COVID-Compromise Study).

There have been reports of a more serious course of COVID-19 infections in patients with a reduced immune system, such as patients with congenital immune disorders, (haematological) malignancies or patients taking medications that suppress the…

Characterization of the immuno-modulatory effects of Tecfidera in multiple sclerosis patients: exploration of drug mechanism and methodological feasibility.

The main purpose of the study is to assess immune cell dynamics in Tecfidera-treated MS patients and untreated healthy subjects, and to explore whether differences in immune cell dynamics exist between both populations. The data generated in this…

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination…

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

This study has been transitioned to CTIS with ID 2023-508897-27-00 check the CTIS register for the current data. Primary:• To compare the efficacy of elranatamab vs lenalidomide Secondary:- To compare the efficacy of elranatamab vs lenalidomide- To…